Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The importance of cost inputs and sensitivity analyses in a cost-effectiveness analysis.

× No keyword cloud information.

6 in total

1. Pitfalls associated with commonly used methods for pharmacoeconomic analyses.

Authors: Donald G Klepser
Journal: Pharmacotherapy Date: 2002-02 Impact factor: 4.705

2. Guidelines for performing a pharmacoeconomic analysis.

Authors: L M Jolicoeur; A J Jones-Grizzle; J G Boyer
Journal: Am J Hosp Pharm Date: 1992-07

Review 3. Managing oncology costs.

Authors: Claiborne E Reeder; Debra Gordon
Journal: Am J Manag Care Date: 2006-02 Impact factor: 2.229

4. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Authors: Michael Pfreundschuh; Lorenz Trümper; Anders Osterborg; Ruth Pettengell; Marek Trneny; Kevin Imrie; David Ma; Devinder Gill; Jan Walewski; Pier-Luigi Zinzani; Rolf Stahel; Stein Kvaloy; Ofer Shpilberg; Ulrich Jaeger; Mads Hansen; Tuula Lehtinen; Armando López-Guillermo; Claudia Corrado; Adriana Scheliga; Noel Milpied; Myriam Mendila; Michelle Rashford; Evelyn Kuhnt; Markus Loeffler
Journal: Lancet Oncol Date: 2006-05 Impact factor: 41.316

5. Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients.

Authors: E A Calhoun; C H Chang; E E Welshman; D A Fishman; J R Lurain; C L Bennett
Journal: Oncologist Date: 2001

6. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.

Authors: Felicetto Ferrara; Roberto Ravasio
Journal: Clin Drug Investig Date: 2008 Impact factor: 2.859

6 in total